CO2021013371A2 - Compuestos y métodos para reducir la expresión de kcnt1 - Google Patents

Compuestos y métodos para reducir la expresión de kcnt1

Info

Publication number
CO2021013371A2
CO2021013371A2 CONC2021/0013371A CO2021013371A CO2021013371A2 CO 2021013371 A2 CO2021013371 A2 CO 2021013371A2 CO 2021013371 A CO2021013371 A CO 2021013371A CO 2021013371 A2 CO2021013371 A2 CO 2021013371A2
Authority
CO
Colombia
Prior art keywords
compounds
methods
kcnt1
reduce
pharmaceutical compositions
Prior art date
Application number
CONC2021/0013371A
Other languages
English (en)
Inventor
Susan M Freier
Huynh-Hoa Bui
Original Assignee
Ionis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ionis Pharmaceuticals Inc filed Critical Ionis Pharmaceuticals Inc
Publication of CO2021013371A2 publication Critical patent/CO2021013371A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

Se proporcionan compuestos, métodos y composiciones farmacéuticas para reducir la cantidad o actividad del ARN de KCNT1 en una célula o sujeto, y en determinadas circunstancias reducir la cantidad de proteína de KCNT1 en una célula o un sujeto. Estos compuestos, métodos y composiciones farmacéuticas son útiles para mejorar al menos un síntoma o característica de una afección neurológica. Dichos síntomas y características incluyen convulsiones, encefalopatía y anomalías del comportamiento. Ejemplos no limitativos de afecciones neurológicas que se benefician de estos compuestos, métodos y composiciones farmacéuticas son la epilepsia de la infancia con crisis focales migratorias (EIMFS), la epilepsia del lóbulo frontal nocturna autosómica dominante (ADNFLE), el síndrome de West y el síndrome de Ohtahara.
CONC2021/0013371A 2019-03-15 2021-10-06 Compuestos y métodos para reducir la expresión de kcnt1 CO2021013371A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819344P 2019-03-15 2019-03-15
US201962884501P 2019-08-08 2019-08-08
PCT/US2020/022680 WO2020190740A1 (en) 2019-03-15 2020-03-13 Compounds and methods for reducing kcnt1 expression

Publications (1)

Publication Number Publication Date
CO2021013371A2 true CO2021013371A2 (es) 2021-10-20

Family

ID=72520445

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0013371A CO2021013371A2 (es) 2019-03-15 2021-10-06 Compuestos y métodos para reducir la expresión de kcnt1

Country Status (18)

Country Link
US (1) US20220177893A1 (es)
EP (1) EP3938514A4 (es)
JP (1) JP2022526267A (es)
KR (1) KR20210141983A (es)
CN (2) CN113661241A (es)
AU (1) AU2020241693B2 (es)
BR (1) BR112021015494A2 (es)
CA (1) CA3133247A1 (es)
CL (1) CL2021002398A1 (es)
CO (1) CO2021013371A2 (es)
CR (1) CR20210519A (es)
IL (1) IL285546A (es)
JO (1) JOP20210254A1 (es)
MX (1) MX2021011132A (es)
PE (1) PE20220168A1 (es)
SG (1) SG11202108625WA (es)
TW (1) TW202102675A (es)
WO (1) WO2020190740A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106816A1 (en) 2018-11-21 2020-05-28 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
WO2023102490A1 (en) * 2021-12-01 2023-06-08 Atalanta Therapeutics, Inc. Compositions and methods for treatment of epilepsies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
JP6336755B2 (ja) * 2010-11-12 2018-06-06 ザ ジェネラル ホスピタル コーポレイション ポリコームに関連する非コードｒｎａ
US20200129538A1 (en) * 2017-06-13 2020-04-30 The Florey Institute Of Neuroscience And Mental Health Compositions and methods for treating conditions associated with gain-of-function mutations in kcnt1

Also Published As

Publication number Publication date
MX2021011132A (es) 2021-10-14
JP2022526267A (ja) 2022-05-24
BR112021015494A2 (pt) 2021-10-05
EP3938514A1 (en) 2022-01-19
CL2021002398A1 (es) 2022-06-03
SG11202108625WA (en) 2021-09-29
PE20220168A1 (es) 2022-01-28
AU2020241693A1 (en) 2021-09-02
US20220177893A1 (en) 2022-06-09
EP3938514A4 (en) 2023-05-03
CN113661241A (zh) 2021-11-16
IL285546A (en) 2021-09-30
JOP20210254A1 (ar) 2023-01-30
CR20210519A (es) 2021-11-24
CN117106778A (zh) 2023-11-24
TW202102675A (zh) 2021-01-16
KR20210141983A (ko) 2021-11-23
AU2020241693B2 (en) 2024-01-04
WO2020190740A1 (en) 2020-09-24
CA3133247A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
CO2021013371A2 (es) Compuestos y métodos para reducir la expresión de kcnt1
RU2020119390A (ru) Применение каннабиноидов при лечении приступов, связанных с синдромом леннокса-гасто
BR112019007383A2 (pt) compostos e métodos para reduzir a expressão de atxn3
CO2020015256A2 (es) Compuestos y métodos para la reducción de la expresión de lrrk2
BR112015014729A2 (pt) estrutura côncava, colheitadeira e método de processamento de uma cultura agrícola
CO2020013433A2 (es) Compuestos y métodos para reducir de la expresión de atxn3
AR063241A1 (es) Cabezal cosechador de cosechadora combinada con tambor alimentador
BR112012013034A2 (pt) métodos e aparelhos para segregação de partículas, incluindo a segregação e a proliferação de células fetais e células-tronco
CO2021016480A2 (es) Células t genomodificadas
AR122744A1 (es) Compuestos y métodos para reducir la expresión de kcnt1
Armed Forces Health Surveillance Center (AFHSC Erectile dysfunction among male active component service members, US Armed Forces, 2004-2013
CO2021012796A2 (es) Compuestos y métodos para modular ube3a-ats
UY39297A (es) Compuestos y métodos para reducir la expresión de kcnt1
CU24418B1 (es) Una cinta de alimentación para una cosechadora de caña de azúcar
AR093463A1 (es) Composicion nutricional para promocionar la saciedad
EA202192527A1 (ru) Соединения и способы для снижения экспрессии kcnt1
AR086738A1 (es) Uso de un anticuerpo anti-cd20 de gran citotoxicidad para la mediacion celular dependiente de anticuerpos (adcc) en el tratamiento de la enfermedad de waldenström
Khan N-nitro-L-arginine, a nitric oxide synthase inhibitor, aggravates iminodipropionitrile-induced neurobehavioral and vestibular toxicities in rats
AR118517A1 (es) Compuestos y métodos para modular ube3a-ats
ES2463190R1 (es) Formas cristalinas de sartanes tales como telmisartán con betabloqueantes
PL415480A1 (pl) Konstrukcja sieczkarni do zbioru roślin energetycznych
Ravishanka et al. Phenytoin/albendazole induced exanthematous eruptions: a case report.
AR119686A1 (es) Compuestos y métodos para reducir la expresión de app
Viktorovna Prospects of agricultural insurance risks development
UY39726A (es) Proceso para la preparación de n-arilformamidinas para proteger plantas frente a enfermedades que so